Gilead Sciences has made a significant acquisition to expand its cell therapy capabilities, but reports vary on the target company and the deal's value. Some outlets indicate that Gilead is acquiring Arcellx for $7.8 billion, while another report mentions the acquisition of Interius Bio for $350 million. The acquisition is seen as a move to enhance Gilead's presence in the cell therapy space, particularly in the area of in vivo cell therapy and CAR T.